

Update from NRS Reproductive Health and Childbirth Specialty Group August 2020



Elsie Inglis, born August 1864, Founder of the Scottish Women's Hospitals

LETTER FROM THE CHIEF MEDICAL OFFICERS OF ENGLAND, NORTHERN IRELAND, SCOTLAND AND WALES. 18th August 2020

This letter details the next steps for COVID-19-related research and the restart of studies paused by COVID-19. Full letter: http://www.nhsresearchscotland.org.uk/uploads/tinymce/CEM_CMO_2020_032.pdf

NIHR IMPLEMENTATION OF THE RESTART FRAMEWORK. TWO MONTH UPDATE

The NIHR [Restart Framework](#), developed in partnership with multiple stakeholders and the devolved nations, aims to restore a fully active portfolio of NIHR research while continuing to support important COVID-19 studies. This update acknowledges that restarting research alongside the restart and recovery of routine clinical services in the NHS is proving complex and challenging. See the first NIHR Restart update [here](#).

The Chief Scientist Office is pursuing several strands of activity to facilitate restart of health and social care research within NHS Research Scotland and have identified a similar set of challenges (and opportunities).

COVID-19 URGENT PUBLIC HEALTH (UPH) STUDIES UPDATE

The initial results of [UKOSS COVID-19 in Pregnancy](#), led by Professor Marian Knight, University of Oxford, have been published.



Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. [Full article](#).

The conclusions indicate that most pregnant women admitted to hospital with SARS-CoV-2 infection were in the late second or third trimester, supporting guidance for continued social distancing measures in later pregnancy. Most had good outcomes, and transmission of SARS-CoV-2 to infants was uncommon. The high proportion of women from black or minority ethnic groups admitted with infection needs urgent investigation and explanation.

COVID-19 URGENT PUBLIC HEALTH (UPH) STUDIES LOOKING FOR SITES IN SCOTLAND

PAN-COVID. Pregnancy and Neonatal Outcomes in COVID-19

A global registry of women with suspected or confirmed SARS-CoV-2 infection in pregnancy and their neonates, understanding natural history to guide treatment and prevention.

CPMS ID: 45571. IRAS: 285220 (Scotland), (282655 England).

CI: Dr Edward Mullins, Imperial College London. Funder: NIHR/UKRI.



Currently more than 160 sites are taking part and a number of international centres have joined.

To register your interest please visit: <https://pan-covid.org/>

Update on Approvals in Scotland: the Scottish Governance Report has been issued and the local R&D Management Approvals are progressing.

NHS Grampian, Highland, Lothian and Tayside are on board. Many thanks!

The study team is very keen to work with all Health Boards in Scotland, if you have any queries or concerns please let us know or contact the PAN-COVID team: pan-covid@imperial.ac.uk.

NHS Research Scotland Restarting Research Patient Survey

A new patient survey has been launched by NHS Research Scotland to capture confidence levels of patients returning to participate in NHS research.

Please distribute widely to colleagues, patients, friends and family.
To complete the survey: <https://www.surveymonkey.co.uk/r/KZ2566Y>

NEW NON-COVID 19 STUDIES SEEKING SITES IN SCOTLAND

GBS3. The clinical and cost-effectiveness of testing for Group B Streptococcus: a cluster randomised trial with economic and acceptability evaluations.

CPMS ID 42782; IRAS 263682. CI: Professor Jane Daniels, University of Nottingham. Funder: NIHR NETSCC.

Please note that criteria for births in GBS3 sites have been reduced to 2500 per annum.

To access the protocol and site selection questionnaire:

<https://nottingham.onlinesurveys.ac.uk/gbs3-site-selection-questionnaire>.



Many thanks to everyone who have expressed their interest!

The study team would like to hear from all sites in Scotland.

If you have any queries or encountered barriers to participation please get in touch with the study team. They will be happy to help to resolve any issues, please contact Sarah Craig at GBS3@nottingham.ac.uk.

POISE (Premature Ovarian Insufficiency Study of Effectiveness of hormonal therapy).

Hormone therapy for premature ovarian insufficiency: randomised trial and long-term evaluation.

Co-CIs: Dr Melanie Davies, University College London Hospitals and Professor Jane Daniels, Nottingham Clinical Trials Unit. Funder: NIHR HTA.



This new clinical trial aims to investigate what is the most effective hormone treatment for women with premature ovarian insufficiency (POI) in the short and long term.

The trial plans to open to recruitment in Autumn 2020, if you are interested in participating or have any further questions please contact the study team at poise@nottingham.ac.uk.

Many thanks to Ayrshire & Arran, Grampian, Greater Glasgow & Clyde, Lothian and Tayside for their interest!

The PARROT-2 Trial. Placental growth factor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspected preeclampsia. CPMS ID 43092; IRAS 265824. CI: Professor Lucy Chappell, KCL.

At present, the study team are only taking on new participating sites that are implementing placental growth factor testing as part of clinical care for pregnant women with suspected pre-eclampsia.

Any interested sites in Scotland would have to implement this test.

PARROT-2



If you are interested please contact Alice Hurrell, for further details, alice.hurrell@kcl.ac.uk.

Please send your Good News, queries or any information that you would like to be included to: Abha (abha.maheshwari@abdn.ac.uk) or Txaro (maria.amezaga@nhs.net)